Abstract Purpose of Review Inhaled environmental exposures cause over 12 million deaths
per year worldwide. Despite localized efforts to reduce environmental exposures, tobacco …

The SPARC (secreted protein acidic and rich in cysteine) protein is matricellular molecule
regulating interactions between cells and their surrounding extracellular matrix (ECM). This …

Silica nanoparticles (SiNPs) have been reported to induce pulmonary fibrosis (PF) with an
unknown mechanism. Recently, the activation of autophagy, a lysosome-dependent cell …

Idiopathic pulmonary fibrosis (IPF) is a progressive, lethal, and chronic lung disease. There
are no effective drug therapies for IPF. Hyperoside, a flavonoid glycoside, has been proven …

Epithelial-mesenchymal transition (EMT) is a phenotype conversion that plays a critical role
in the development of pulmonary fibrosis (PF). It is known that snail could regulate the …

The clinical course in idiopathic pulmonary fibrosis (IPF) is highly heterogeneous, with some
patients having a slow progression and others an accelerated clinical and functional …

Idiopathic pulmonary fibrosis (IPF) is an inexorably progressive lung disease of unknown
origin. Prognosis is poor, with limited treatment options available, and the median survival …

Objectives Macrophage-mannose receptor, CD206, is a marker of alternatively activated
macrophages. Activated macrophages play key roles in DM. Interstitial lung disease (ILD) is …

In this study we investigated the implication of NLRP3 inflammasomes in the pathogenesis
of idiopathic pulmonary fibrosis (IPF) and rheumatoid arthritis–usual interstitial pneumonia …

Nintedanib (NIN) and pirfenidone are the only approved drugs for the treatment of Idiopathic
Pulmonary Fibrosis (IPF). However, NIN and pirfenidone have low oral bioavailability and …